Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002823 | 0.86 | LMNA (0.42) | KMT2ACNR2ALDH1A1GAAHSD17B10 | |
| SCHEMBL10082999 | 0.83 | KMT2A (0.47) | KMT2AMEN1AKR1C1CYP2C19ALDH1A1 | |
| SCHEMBL15385491 | 0.80 | CYP2C19 (0.49) | KMT2AMEN1AKR1C1CYP2C19AKR1C3 | |
| SCHEMBL10083734 | 0.77 | KMT2A (0.46) | KMT2AMEN1AKR1C1CYP2C19ALDH1A1 | |
| SCHEMBL10083000 | 0.77 | ALDH1A1 (0.55) | AKR1C1ALDH1A1OPRM1 | |
| SCHEMBL1561226 | 0.76 | HDAC4 (0.59) | KMT2AMEN1AKR1C1CYP2C19OPRM1 | |
| SCHEMBL13386466 | 0.75 | CNR2 (0.42) | CNR2OPRM1OPRL1 | |
| SCHEMBL5735643 | 0.74 | CNR2 (0.45) | CNR2GAAOPRM1OPRL1 | |
| SCHEMBL1465031 | 0.74 | AKR1C1 (0.55) | AKR1C1CYP2C19 | |
| SCHEMBL10083309 | 0.74 | KDM4E (0.46) | KMT2AAKR1C1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | KMT2A 1079/4885MEN1 4199/4885AKR1C1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.